Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JAMA: ‘General Wellness’ Apps Could Pose Patient Safety Quandary

Executive Summary

Four Harvard Law attorneys who specialize in bioethics say the rapidly changing area may require a new regulatory approach.

You may also be interested in...



Wellness Devices May Have More Leeway In FDA Final Guidance

As new mobile health technologies such as wearables and mobile health apps come to market, the US FDA's new guidance is intended to give manufacturers a better idea of what kinds of low-risk wellness products the agency will allow to avoid regulation.

It’s A Class I Recall For Baxter’s WatchCare Device

Radiofrequencies from the incontinence-sensing devices may interfere with other medical equipment in a hospital setting. 

It’s A Class I Recall For Baxter’s WatchCare Device

Radiofrequencies from the incontinence-sensing devices may interfere with other medical equipment in a hospital setting. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel